NVS vs RVMD
Novartis AG vs Revolution Medicines, Inc. — AI-powered side-by-side comparison
VS
RVMD
Revolution Medicines, Inc.
61
Buy
| Metric | NVS | RVMD |
|---|
| AI Score |
75
|
61
|
| Price |
$154.64
|
$205.54
|
| P/E Ratio |
23.55×
|
-23.20×
|
| ROE |
30.5%
|
-69.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
0.0%
|
| Debt / Equity |
1.18×
|
0.25×
|
| Dividend Yield |
2.9%
|
0.0%
|
| RSI (14) |
57.7
|
70.9
|
| Beta |
0.462
|
1.403
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus RVMD.
NVS leads by 14 points.
NVS scores 75/100 (Buy) versus RVMD at 61/100 (Buy).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
RVMD Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 9.4x prices in significant intangible value — Value
- ROE of only -54.1% -- cheap may mean cheap for a reason — Value
- RSI at 71 is in overbought territory — Technical